Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL21253146 | 1.00 | DNM1 (0.44) | DNM1OPRM1CHRNB2CHRNB4CHRNA4 | |
| Bromide SCHEMBL238106 | 1.00 | DNM1 (0.44) | DNM1OPRM1CHRNB2CHRNB4CHRNA4 | |
| Bromide SCHEMBL28501646 | 1.00 | DNM1 (0.44) | DNM1OPRM1CHRNB2CHRNB4CHRNA4 | |
| Bromide SCHEMBL4623968 | 1.00 | DNM1 (0.44) | DNM1OPRM1CHRNB2CHRNB4CHRNA4 | |
| Bromide SCHEMBL239119 | 1.00 | DNM1 (0.44) | DNM1OPRM1CHRNB2CHRNB4CHRNA4 | |
| Bromide SCHEMBL8471902 | 1.00 | DNM1 (0.44) | DNM1OPRM1CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL12946732 | 0.97 | OPRM1 (0.46) | DNM1OPRM1CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL37596 | 0.97 | OPRM1 (0.46) | DNM1OPRM1CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL20747520 | 0.97 | OPRM1 (0.46) | DNM1OPRM1CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL1024279 | 0.97 | OPRM1 (0.46) | DNM1OPRM1CHRNB2CHRNB4CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 769 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022012-A1 | METHOD FOR CATALYTICALLY DRY REFORMING METHANE | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2026-01-22 | — | — | US | claimed |
| US-20260007731-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME | BLUEWILLOW BIOLOGICS, INC. (US) | 2026-01-08 | — | — | US | claimed |
| US-20250281910-A1 | FIBROUS SILICA LANTHANUM OXIDE-BASED CATALYST FOR DRY REFORMING OF METHANE AND METHODS OF PREPARATION THEREOF | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-09-11 | — | — | US | claimed |
| EP-4507722-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | Bluewillow Biologics, Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| US-12215025-B1 | Fibrous silica zinc oxide-supported nickel catalyst for dry reforming of methane and methods of preparation thereof | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-02-04 | — | — | US | claimed |
| US-11978622-B2 | Aqueous and semi-aqueous cleaners for the removal of post-etch residues with tungsten and cobalt compatibility | ENTEGRIS, INC. (US) | 2024-05-07 | — | — | US | claimed |
| US-20240058434-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2024-02-22 | — | — | US | claimed |
| US-20240010870-A1 | UV-BLOCKING COATINGS AND ANTI-FOGGING AND SUPERHYDROPHOBIC COATINGS | BAR ILAN UNIVERSITY (IL) | 2024-01-11 | — | — | US | claimed |
| WO-2023200764-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2023-10-19 | — | — | WO | claimed |
| WO-2023133143-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOEMULSION VACCINES AND METHODS OF USING THE SAME | BLUEWILLOW BIOLOGICS, INC. (US) | 2023-07-13 | — | — | WO | claimed |
| US-20040191854-A1 | Papanicolau staining process | CYTYC CORPORATION | 2004-09-30 | — | — | US | claimed |
| US-6762027-B2 | EXTRACTING PREFERENTIAL NUCLEOTIDE SEQUENCE FROM TISSUE; OBTAIN TISSUE SAMPLE, EXPOSE TO DISRUPTION MIXTURE, BIND NUCLEIC ACID TO SOLID PHASE, RECOVER NUCLEOTIDE SEQUENCES | APPLERA CORPORATION | 2004-07-13 | — | — | US | claimed |
| US-20040009655-A1 | Method for manufacturing metal line contact plugs for semiconductor devices | HYNIX SEMICONDUCTOR INC. (KR) | 2004-01-15 | — | — | US | claimed |
| EP-1354036-A2 | COMPOSITIONS, METHODS, AND KITS FOR ISOLATING NUCLEIC ACIDS USING SURFACTANTS AND PROTEASES | Applera Corporation (US) | 2003-10-22 | — | — | EP | claimed |
| US-20020177139-A1 | Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases | APPLIED BIOSYSTEMS, LLC | 2002-11-28 | — | — | US | claimed |
| WO-2002090539-A2 | COMPOSITIONS, METHODS, AND KITS FOR ISOLATING NUCLEIC ACIDS USING SURFACTANTS AND PROTEASES | APPLERA CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
| US-6248161-B1 | Preparation of permanent color inks from water-soluble colorants using specific phosphonium salts | HEWLETT-PACKARD COMPANY | 2001-06-19 | — | — | US | claimed |
| EP-0217197-B1 | DETERMINATION OF BILIRUBIN AND CORRESPONDING REAGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1991-10-16 | — | — | EP | claimed |
| US-4849531-A | Process for the preparation of 2,3-epoxyamides | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-18 | — | — | US | claimed |
| US-4711959-A | REACTING 2-ALKYLSULPHONYL-PYRIMIDINE WITH CYANAMIDE OR METAL SALT OF CYANAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1987-12-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022012-A1 | METHOD FOR CATALYTICALLY DRY REFORMING METHANE | RNF4, SOD1, HRH4 | DNM1 650/4885OPRM1 3199/4885CHRNB2 1815/4885 |
| US-20260007731-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME | CD14, CD47, MYD88 | DNM1 2280/4885OPRM1 2529/4885CHRNB2 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.